Drug Profile


Alternative Names: IQB-9302

Latest Information Update: 25 May 2004

Price : $50

At a glance

  • Originator IQB
  • Class Analgesics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 25 May 2004 No development reported - Clinical-Phase-Unknown for Pain in Spain (unspecified route)
  • 14 Aug 2002 A preclinical study has been added to the Pain Control pharmacodynamics section
  • 14 Feb 2001 Investigation in Pain in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top